
|Videos|September 23, 2020
Management of Adverse Effects in R/R HER2+ mBC
Advertisement
Counseling patients and the management of adverse effects of newer regimens in relapsed/refractory HER2+ metastatic breast cancer as well as advice for oncology nurses.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5


































